Improving multivariable prostate cancer risk assessment  by Maweni, R. et al.
Abstracts / International Journal of Surgery 36 (2016) S31eS132 S123Aim: Intravesical injections of botulinium toxin type A can be offered for
refractory symptoms of overactive bladder. This project aimed to:
(1) Assess patient satisfaction with intravesical injections admin-
istered under local anaesthetic.
(2) Evaluate service change within this Regional Unit.
(3) Use outcome tso improve service delivery.
Method: 38 patients received injections under LA November-April 2014.
During post-treatment telephone review, patients completed:
(i) the validated TSQM patient satisfaction questionnaire
(ii) a ‘recommend to a friend’ Analogue Scale
(iii) a Likert-type scale for LA versus GA
Quality of life pre and post-procedure was evaluated using ICIQ-LUTS.
Four-domain TQSM scores were calculated. T-Test was performed on pre-
and-post injection LUTS scores.
Result: Twenty-ﬁve patients were successfully contacted. Validated TSQM
questionnaires revealed a mean of 80% of the maximum score for clinical
effectiveness (SD 21). Overall global satisfaction was 78%. Fifty-six percent
of patients indicated a preference for GA compared with LA. Patients
expressing a preference for LA had greater symptom improvement.
Conclusion: Botox injections administered under LA were effective,
demonstrated by the improvement in LUTS scores and the high level of
satisfaction. A majority expressed a preference for LA; the greater symp-
tom improvement in this group may be a confounding factor.http://dx.doi.org/10.1016/j.ijsu.2016.08.454
0352: AN IRISH PROSTATE CANCER RISK CALCULATOR
R. Foley 1,*, K. Murphy 2, R. Maweni 3, T. Lynch 4, R. Power 4, G. Durkan 4,
F. O'Brien 4, K. O'Malley 4, D. Galvin 4, T. Brendan Murphy 2, R. William
Watson 1. 1 School of Medicine, University College Dublin, Ireland; 2 School of
Mathematical Sciences, University College Dublin, Ireland; 3Croydon
University Hospital, London, UK; 4 Irish Prostate Biopsy Collaborative, Ireland.
Introduction:Accurate risk stratiﬁcation of patients pre-biopsy is essential
for the diagnosis of prostate cancer (PCa). The objective of this studywas to
build a risk calculator to facilitate the decision for prostate biopsy in
Ireland.
Method: The clinical information of 4,808 patients from 8 Irish tertiary
centres was analysed. A risk calculator for the diagnosis of PCa and another
for the diagnosis of high grade (Gleason 7) PCa were created via logistic
regression. The components of the risk calculators are age, digital rectal
examination, family history, prior negative biopsy and PSA level.
Result: The Irish PCa Risk Calculator achieved AUC values of 0.67 and 0.73
in the prediction of PCa and high grade PCa respectively. This was a sta-
tistically signiﬁcantly improvement over PSA (p<0.01) with AUC values for
PSA of 0.60 and 0.66 for the prediction of PCa and high grade PCa. The Irish
PCa risk calculator also demonstrated a net beneﬁt on decision curve
analysis and a suitable calibration in each cohort.
Conclusion: An Irish PCa risk calculator created from a national collection
of patients can allow for individualised risk stratiﬁcation and can be used
to improve clinical decision-making in Irish men under investigation for
PCa.http://dx.doi.org/10.1016/j.ijsu.2016.08.455
0366: IMPROVING MULTIVARIABLE PROSTATE CANCER RISK
ASSESSMENT
R. Maweni 1,*, R. Foley 2, K. Murphy 3, G. Durkan 4, R. Power 4, F. O'Brien 4,
K. O'Malley 4, D. Galvin 4, B. Murphy 3, W. Watson 2. 1Croydon University
Hospital, London, UK; 2University College Dublin, School of Medicine, Dublin,
Ireland; 3 School of Mathematical Sciences, University College Dublin, Dublin,
Ireland; 4 Irish Prostate Biopsy Collaborative, Dublin, Ireland.Introduction: In order to diagnose prostate cancer (PCa) effectively, the
best possible risk factors should be utilised. We assessed the performance
of two well-validated PCa risk calculators to analyse the use of prostate
volume and a novel PCa biomarker (pro-PSA) in PCa prediction.
Method: The risk of high-grade PCa (Gleason 7) in 2,001 patients from 6
tertiary referral centres was calculated according to the two PCa risk cal-
culators. Predictions were analysed using ROC analysis, calibration analysis
and decision curve analysis. In a subset of 222 patients, risk predictions
were calculated that included pro-PSA.
Result: The addition of prostate volume signiﬁcantly improved the per-
formance of high-grade PCa prediction, with an AUC of 0.74 compared to
0.69 (p<0.001). The addition of pro-PSA further improved risk prediction
with an AUC of 0.78 compared to 0.72 (p¼0.04).
Conclusion: The performance of these PCa risk calculators demonstrates
that prostate volume has the potential to improve PCa diagnosis. Further-
more, the incorporation of the pro-PSA allowed each patient’s risk to be
more accurately quantiﬁed. Individual patient risk calculation using prostate
volume and pro-PSA can be undertaken in order to allow for a systematic
approach to patient risk stratiﬁcation and to aid in the diagnosis of PCa.http://dx.doi.org/10.1016/j.ijsu.2016.08.456
0376: REJECTING REFERRALS FOR ASYMPTOMATIC NON-VISIBLE HAE-
MATURIA: IMPLICATIONS OF A CHANGE IN PRACTICE
M. Kamarizan*, A. Cox, M. Hunter, J.R. Wilson, D.J. Painter, A.C. Carter. Royal
Gwent Hospital, Newport, UK.
Introduction: The NICE NG12 guidance for urgent suspected cancers(USC)
suggests that asymptomatic non-visible haematuria(aNVH) need not be
seen as USC. Whilst implementing NG12, we also present the early
outcome of rejecting referrals for aNVH entirely.
Method: USC haematuria referrals to a large district general hospital from
April to November 2015 were strictly vetted prospectively against NG12
recommendations, and compared to data from a similar time period prior to
implementation. Simultaneously aNVH referrals were rejected in writing.
Result: In 8 months, 676 patients were seen in a one stop haematuria clin-
ic(OSHC); 352 pre-NG12 implementation(cohort 1), and 324 after-
wards(cohort 2). In cohort 1, 212 had visible haematuria(VH), and 140 had
non-visible haematuria(NVH) with 34 cancers diagnosed. Thirteen of these
were either high risk non-muscle invasive(HRNMIBC) or muscle invasive(-
MIBC)bladdercancer.Of thosewithNVH,only1 lowrisknon-muscle invasive
bladder cancer(LRNMIBC) was diagnosed. In cohort 2, 39 cancers were
diagnosed; 11 HRNMIBC and 4 MIBC. Seventy-six aNVH referrals were
rejected.Average referral to treatment timeimprovedfrom39days to18days.
Conclusion: No signiﬁcant tumour was found in patients referred with
aNVH pre-implementation. After implementation, and rejecting patients
with aNVH, patients with bladder cancer were seen and treated earlier.http://dx.doi.org/10.1016/j.ijsu.2016.08.457
0433: PROCEDURES FOR PENILE STRICTURES: OPTIONS AND OUT-
COMES AT 7 YEARS
D. Evans*, I. Rudd, R. Krishnan. Kent & Canterbury Hospital, Canterbury, Kent,
UK.
Aim: Penile urethral strictures can be treated by a variety of procedures,
often in tertiary care centres. We present our experience and outcomes
over a 7 year period at a District General Hospital.
Method: Between November 2008 and December 2015, 101 operations
were performed by a single surgeon in seventy patients with penile ure-
thral strictures. Twenty also had bulbar urethral involvement. Procedures
included two-stage urethroplasty with buccal mucosal graft (BMG) (49
ﬁrst/31 second stage), single stage dorsal BMG urethroplasty (4), Orandi
patch (5), meatotomy (7), and perineal urethrostomy (5). Median age was
51.3 years and median stricture length was 5cm.
Result: 30% of penile strictures were iatrogenic, 30%were BXO-related, and
24% were failed hypospadias repairs. A successful outcome was seen in
90%. Four patients (5.7%) required minor revision prior to ﬁnal
